By Notice dated October 8, 1999, and published in the Federal Register on October 18, 1999, (64 FR 56226), Chirex Technology Center, Inc., DBA Chirex Cauldron, 383 Phoenixville Pike, Malvern, Pennsylvania 19355, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of amphetamine (1100), a basic class of controlled substance listed in Schedule II.
The firm plans to bulk manufacture amphetamine and its salts for product development.
DEA has considered the factors in title 21, United States Code, section 823(a) and determined that the registration of Chirex Technology Center, Inc., DBA Chirex Cauldron to manufacture amphetamine is consistent with the public interest at this time. DEA has investigated the firm to ensure that the company's registration is consistent with the public interest. The investigation included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed above is granted.
Dated: June 7, 2000.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 00-15688 Filed 6-21-00; 8:45 am]
BILLING CODE 4410-09-M